STAT+: Why this health tech investor thinks AI could bring the ‘learning health system’ to life
Morgan Cheatham, the new head of health care and life sciences at Breyer Capital, on his investment strategy.
In April, investor Morgan Cheatham was granted access to a significant fortune and told to go find the next transformational ideas in health care and life sciences. Now, he’s sharing a little more about what exactly he’ll do with it.
Cheatham is the new head of health care and life sciences at Breyer Capital, the investment office of Jim Breyer, who is known for savvy early investments in companies like Facebook and Etsy. Breyer’s health care portfolio includes highly valued companies like Lyra Health and OpenEvidence.
At 29, Cheatham is no slouch himself. In his previous job at Bessemer Venture Partners, he worked on investments for two of the most prominent companies in digital health: Hinge Health, the virtual physical therapy company that went public last month, and Abridge, the booming ambient scribing company. In May, he completed his medical degree at Brown University, and in June, began a combined pediatrics and genetics residency program at Boston Children’s Hospital and Harvard. Cheatham has also become a leading advocate for health artificial intelligence and works with both the New England Journal of Medicine AI and the Coalition for Health AI.
